Press Room

Event

AAPS 2025 PharmSci 360

Start
Sunday, November 09, 2025
End
Wednesday, November 12, 2025
Location: San Antonio, TX, United States
Booth Number: 2943

Hovione is exhibiting at the AAPS 2025 PHarmSCi 360, a convener of the pharmaceutical science community, bringing together thousands of scientists from across the world. PharmSci 360 combines all the energy of a large scientific conference with the intimacy of a small niche meeting because of its unique programming structure built on five tracks that cover the pharmaceutical development process. 

Don't miss our experts' presentations in San Antonio

Symposium Presentation, 302 ABC

Addressing Practical Challenges in CM via Novel Hardware and Automation

Monday, November 10 | 9:00 AM - 9:30 AM 

Speaker: Sarang Oka, Fellow Scientist - Technology Intensification

Short description: 

This work tackles critical operational challenges in continuous manufacturing processes for oral drug products, focusing on scalability, automation, and efficiency. Key issues include the complexity and manual nature of residence time distribution (RTD) experiments, non-automated execution of multi-point design of experiments (DOEs), and throughput limitations tied to existing continuous manufacturing equipment for oral solids. Innovative hardware and automation-based solutions have been developed to address the aforementioned challenges.

Key learnings of the session:

  • Participants will learn of automated, novel approaches to execute residence time distribution experiments in CM process trains.
  • Participants will learn of automated, novel approaches to execute DOEs in CM process trains, coupled with automated sampling with the goal of one-person DOE execution.
  • Participants will learn of a novel approach that combines batch and continuous processing in a single process train and how built-in modularity enables the operation over a wide throughput range.

Rapid Fire Presentation, 225 AB

Enhancing Biorelevance: Unveiling Enzymatic Impact on Simulated GI Dissolution

Monday, November 10 | 3:30 PM - 3:45 PM

Speaker: Catarina Chendo, MS, Analytical Scientist

Join Hovione at our poster presentations

Polymer Interactions with Dissolution Media: A Key Consideration in Method Development for Amorphous Solid Dispersions

Tuesday, November 11, 2025 | 9:30 AM - 10:30 AM

Presenting Author: Catarina Chendo, Analytical Scientist

Optimizing Biologics Formulation: Synthetic Sugars for Improved Stability and Viscosity

Tuesday, November 11, 2025 | 2:30 PM - 3:30 PM CT

Presenter (non-author): Inês Matos, R&D Manager

ASD Formulation to Unit Dosage Form: Integrated Drug Product Development with Dispersome

Tuesday, November 11, 2025 | 3:30 PM - 4:30 PM

Presenting Author: Inês Ramos, Ph.D., R&D Manager

Special poster collection

Optimizing Biologics Formulation: Synthetic Sugars for Improved Stability and Viscosity

Wednesday, November 12, 2025 | 10:30 AM - 11:25 AM 

Location: Poster Forum 4, Exhibit Hall 3&4

Speaker: Ines Matos, Hovione

 

Meet the Hovione team at booth # 2943

This is the perfect opportunity to speak with our experts and learn how a Specialist Integrated CDMO can deliver your entire project from one site, giving you the benefit of compressed timelines, seamless project management and knowledge, and increased sustainability.

Schedule a meeting today.

schedule a meeting
https://go.hovione.com/l/47122/2014-08-06/9grc

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping
News Medical Life Sciences, 1 June 2026

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026

Every year, the largest bank in Portugal, Caixa Geral de Depósitos recognizes some of Portugal’s brightest young minds through the Caixa +Mundo Awards, providing nearly €800,000 in scholarships to students as they pursue higher education. In this year´s edition, Caixa named the award bestowed upon students pursuing science for Diane Villax. This prestigious honor places Diane Villax among the award’s namesakes – a distinguished group of prominent personalities who have made notable contributions to Portugal´s socio-economic, cultural, political and scientific development over the last 50 years, such as António Ramalho Eanes, Mário Soares, José Saramago, Sophia de Mello Breyner, Leonor Beleza, Elvira Fortunato, Rui Nabeiro, Américo Amorim, and José Manuel de Mello. Diane Villax will also honor the seven scientific award winners by personally meeting with each of them, and following their journeys as future innovators and leaders. But this honor is about far more than one individual. It is a celebration of an entire organization and the people behind it. For 67 years, generations of dedicated teams have worked together with passion, purpose, and excellence to manufacture life-saving medicines and advance science that has a real impact on people. This recognition belongs to all of us.    

News

Prestigious Caixa +Mundo Award named in honor of Diane Villax

May 14, 2026

CDMO Hovione and Industrial Design Consultancy (IDC) have announced that their new single-use capsule-based nasal delivery device is now available exclusively as part of an integrated platform that includes Hovione’s intranasal drug development and manufacturing services. The companies partnered in 2023 with plans for development of two capsule-based devices for intranasal delivery: the single-use device and a multidose device. Read the full article at OINDPnews.com      

Press Clipping
OINDP - Orally inhaled and nasal drug products news, May 11, 2026

Hovione and IDC announce new single-use capsule-based intranasal delivery device for dry powder formulations

May 11, 2026